In a trial run by Verve Therapeutics, a Cambridge–based biotech company, researchers discovered that a single infusion of a gene-editing treatment called VERVE-101 was able to reduce cholesterol levels in patients. This treatment was tested in individuals with hereditary conditions that made them susceptible to developing clogged arteries and heart attacks. Scientists were able to use CRISPR editing techniques to tweak liver gene cells. The researchers “turned off” a cholesterol-raising gene called PCSK9, which is found in the liver, in order to lower LDL-C — sometimes called "bad" cholesterol — which causes plaque to build up in arteries in the first place.

PCSK9 was lowered by as much as 84 percent in the cohorts that received higher infusion rates of the treatment. At those higher treatment doses, Verve scientists said that the reduction of those LDL-C-related proteins lasted 2.5 years in previous studies on primates.

Verve Therapeutics

From a clinical standpoint, this gene editing therapy has the potential to disrupt the current standard treatment for high cholesterol. The current go-to's include prescription statins and PCSK9 inhibitors, but they require strict adherence and can have bad side effects like muscle pain and memory loss.

CRISPR, while seemingly miraculous, is a long way from replacing daily medications though. According to Nature, two of the 10 participants in the study suffered from a “cardiovascular event” that coincided with the infusion. Verve says one was not related to the treatment at all and the second was “potentially related to treatment due to proximity to dosing.” The use of a gene-editing technology will always carry some risk because the edits could occur elsewhere in the genome.

Before a single infusion therapy for high cholesterol can reach consumers, the FDA mandates that the treatment will need to be studied for up to 15 years. Verve recently received FDA clearance for an Investigational New Drug Application for VERVE-101, meaning that the company can begin to conduct trials in the US. The current trials in New Zealand and the United Kingdom will look for willing clinical trial participants to expand the study.

A Parkinson’s patient can now walk 6km (3.7 miles) thanks to an implant targeting the spinal cord. The Guardian reports that the man — 62-year-old “Marc” from Bordeaux, France — developed severe mobility impairments from the degenerative disease. “I practically could not walk anymore without falling frequently, several times a day,” he said in a press release announcing the breakthrough. “In some situations, such as entering a lift, I’d trample on the spot, as though I was frozen there, you might say.” Wearing the spinal implant allows him to walk “almost normally” as the research team eyes a full clinical trial.

Marc underwent a “precision neurosurgical procedure” two years ago at Lausanne University Hospital (CHUV), which helped facilitate the research. The surgery fitted him with an electrode field placed against his spinal cord and an electrical impulse generator under the skin of his abdomen. Although conventional Parkinson’s treatments often target brain regions affected by the loss of dopamine-producing neurons, this approach instead focuses on the spinal area associated with activating leg muscles for walking.

The procedure used a personalized map of Marc’s spinal cord, identifying the specific locations signaling leg movements. He wears a movement sensor on each leg that tells the implant he’s trying to walk; it then switches on and sends electrical impulses to the targeted spinal neurons, adapting to his movement in real-time.

GABRIEL MONNET via Getty Images

“In response to precise stimulation of the lumbar spinal cord, I’ve observed for the first time remarkable improvements of gait deficits due to Parkinson’s disease,” project supervisor Jocelyne Bloch, professor and neurosurgeon at CHUV Lausanne University hospital, said in a webinar discussing the patient’s success. “I really believe that these results open realistic perspectives to develop a treatment.”

The patient says he could walk practically normally with the stimulation after several weeks of rehab. He now wears it for around eight hours daily, only turning it off when sleeping or lying down for a while. “I turn on the stimulation in the morning and I turn off in the evening,” he said. “This allows me to walk better and to stabilise. Right now, I’m not even afraid of the stairs anymore. Every Sunday I go to the lake, and I walk around 6 kilometres. It’s incredible.”

The researchers caution that there’s still a vast chasm between tailoring the approach to one person vs. optimizing it for wide-scale use. Co-leads Grégoire Courtine and Bloch are working on a commercial version of the neuroprosthetic in conjunction with Onward Medical. “Our ambition is to provide general access to this innovative technology to improve the quality of life of Parkinson’s patients significantly, all over the world,” they said.

Michael J. Fox Foundation

In the meantime, research on six new patients will continue in 2024. The team says a “generous donation” of $1 million from the Michael J. Fox Foundation for Parkinson’s Research is funding the upcoming work. In 2021, the actor’s organization announced it had contributed over $1.5 billion to Parkinson’s research.

At least 15 visitors at Yuga Labs’ ApeFest, a celebration of the marvels of Bored Ape Yacht Club NFTs, may have experienced serious eye injuries. Bloomberg reports that multiple people attending the NFT event in Hong Kong last weekend say they experienced vision problems, which they suspect stem from the event’s stage lighting. Some of the attendees claim doctors subsequently diagnosed them with photokeratitis (aka “welder’s eye”), caused by exposure to ultraviolet rays.

“Woke up in the middle of the night after ApeFest with so much pain in my eyes that I had to go to the hospital,” the user Crypto June posted on X (via Coin Telegraph). “Doctor told me it was due to the UV from stage lights.” User @docwagmi suspected that the “ape friends” reporting problems appeared to have been “up close with us front stage.” 

@crypto_birb / X

Meanwhile, Adrian Zduńczyk wrote on X, “To all my friends who suffer now: go get your eyes checked. You’ve likely most literally got your eyes burnt with UV like I did, which requires medications, eye drops, eye protection, antibiotics and specialist care. Don’t ignore this health hazard. Without proper treatment, it may cause long lasting vision impairment and other serious damage.” Zduńczyk wrote that seeking medical attention quickly appears to have spared him long-term damage. “My vision was tested as close to perfect with no serious cornea damage, luckily.”

Yuga Labs briefly addressed the issue on X, saying it’s “aware of the eye-related issues that affected some of the attendees of ApeFest,” while claiming it’s “proactively reaching out to individuals since yesterday to try and find the potential root causes.” The company downplayed the number of people reporting issues, adding, “Based on our estimates, we believe that much less than 1% of those attending and working the event had these symptoms.” The NFT company advised attendees experiencing symptoms to “seek medical attention just in case.”

X users seemed none too pleased with Yuga Labs’ PR response:

The potentially dangerous incident echoes one in 2017 when attendees of a HypeBeast party reported eye damage. The event’s DJ later reported that the lighting contractor used Philips bulbs that emit UV-C, often used as a disinfectant.

At least 15 visitors at Yuga Labs’ Apefest, a celebration of the marvels of Bored Ape Yacht Club NFTs, may have experienced serious eye injuries. Bloomberg reports that multiple people attending the NFT event in Hong Kong last weekend say they experienced vision problems, which they suspect stemmed from the event’s stage lighting. Some of the attendees claim doctors subsequently diagnosed them with photokeratitis (aka “welder’s eye”), caused by exposure to ultraviolet (UV) light.

“Woke up in the middle of the night after Apefest with so much pain in my eyes that I had to go to the hospital,” the user Crypto June posted on X (via Coin Telegraph). “Doctor told me it was due to the UV from stage lights.” User @docwagmi suspected that the “ape friends” reporting problems appeared to have been “up close with us front stage.” 

@crypto_birb / X

Meanwhile, Adrian Zduńczyk wrote on X, “To all my friends who suffer now: go get your eyes checked. You’ve likely most literally got your eyes burnt with UV like I did, which requires medications, eye drops, eye protection, antibiotics and specialist care. Don’t ignore this health hazard. Without proper treatment, it may cause long lasting vision impairment and other serious damage.” Zduńczyk wrote that seeking medical attention quickly appears to have spared him long-term damage. “My vision was tested as close to perfect with no serious cornea damage, luckily.”

Yuga Labs briefly addressed the issue on X, saying it’s “aware of the eye-related issues that affected some of the attendees of ApeFest,” while claiming it’s “proactively reaching out to individuals since yesterday to try and find the potential root causes.” The company downplayed the number of people reporting issues, adding, “Based on our estimates, we believe that much less than 1% of those attending and working the event had these symptoms.” The NFT company advised attendees experiencing symptoms to “seek medical attention just in case.”

X users seemed none too pleased with Yuga Labs’ PR response:

The potentially dangerous incident echoes one in 2017 when attendees of a HypeBeast party reported eye damage. The event’s DJ later reported that the lighting contractor used Philips bulbs that emit UV-C, often used as a disinfectant.

The Chan Zuckerberg Initiative is opening a research center in New York City dedicated to developing new techniques for early disease detection and treatment. CZ Biohub NY, as it’s being called, will work with Columbia, Rockefeller and Yale universities to better learn how immune cells detect and attack specific diseases, and eventually use this insight to engineer cells that could do the job more precisely.

The charitable organization headed by Priscilla Chan and Meta CEO Mark Zuckerberg has committed $250 million to the effort, according to STAT, alongside investments of $10 million each from the State of New York and New York City. In a blog post announcing CZ Biohub NY, the Chan Zuckerberg Initiative said it will start by focusing on cancers and other diseases that often go undetected until they’ve advanced to the point of being difficult or impossible to treat. That includes “ovarian and pancreatic cancers; neurodegenerative diseases, including Parkinson’s and Alzheimer’s; as well as aging and autoimmunity,” CZI says.

CZ BioHub NY aims to get to the bottom of how immune cells work, down to their ability to spot tissue-specific changes that can be among the earliest indications of a disease’s onset. Then, its researchers hope to be able to create cells that can sniff out these abnormalities even earlier than they’re currently able, and be sent to the disease sites directly for more effective treatment. These bioengineered immune cells would “scout, report, and repair damage to our cells before it leads to serious illnesses,” said Chan.

The New York hub is the latest in CZI’s growing network of research institutions, and joins three others that have been established in San Francisco, Chicago, and Redwood City. All have pledged to break ground on their respective scientific goals within a time frame of 10-15 years. Now, according to STAT, the New York biohub just needs to secure a site to work out of.

In a study from Oxford University, researchers found that by using a combination of wearable sensor data and machine learning algorithms the progression of Parkinson’s disease can be monitored more accurately than in traditional clinical observation. Monitoring movement data collected by sensor technology may not only improve predictions about disease progression but also allows for more precise diagnoses.

Parkinson’s disease is a neurological condition that affects motor control and movement. Although there is currently no cure, early intervention can help delay the progression of the disease in patients. Diagnosing and tracking the progression of Parkinson's disease currently involves a neurologist using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) to assess the patient's motor symptoms by assigning scores to the performance of specific movements. However, because this is a subjective, human analysis, classification can be inaccurate.

In the Oxford study, 74 patients with Parkinson’s were monitored for disease progression over a period of 18 months. The participants wore wearables with sensors in different regions of the body: on the chest, at the base of the spine and on each wrist and foot. These sensors — which had gyroscopic and accelerometric capabilities — kept tabs on 122 different physiological measurements, and tracked the patients during walking and postural sway tests. Kinetic data was then analyzed by custom software programs using machine learning.

Oxford

The sensor data collected by the wearables were compared to standard MDS-UPDRS assessments, which are considered the gold standard in current practice. That traditional test, in this study's patients "did not capture any change" while the sensor-based analysis "detected a statistically significant progression of the motor symptoms" according to the researchers.

Having more precise data on the progression of Parkinson's isn't a cure, of course. But the incorporation of metrics from wearables could help researchers confirm the efficacy of novel treatment options.

Tracking your fitness and health just got easier if you use MyFitnessPal and Google's Wear OS. The MyFitnessPal smartwatch app offers a way to keep track of your health stats, including calorie intake and gym gains. While this worked well, it has also been limited since you couldn't edit or input your data directly on your wearable device. However, the latest app update changes things for the better.

In a recent blog post, MyFitnessPal announced updates that will make tracking and logging easier on Wear OS. Now, users can track and log without pulling out their phones. When wearing compatible Android smartwatches, users will have access to new watch tiles and complications — which will give them the ability to log foods they eat regularly while keeping track of daily nutritional intake, like sugar, fiber, fats, calories and even hydration. Users will also be able to see a quick snapshot of their entire day right from their wrists.

This feature will be available to users with a smartwatch running Wear OS, like the new Pixel Watch 2. The MyFitnessPal app is available for download from the Google Play Store.

While this feature isn't entirely new to the MyFitnessPal app on smartwatches — Apple Watch users have had this option for a while — it’s good news that people using Wear OS have another way to track.  Monitoring our health and wellness is important and can be easily neglected when we just don't have the time. Any innovation, big or small, that makes keeping up with health stats easier is always a good move. Now if only they could figure out a way to burn and log calories without the exercise.

The ARC nerve stimulation therapy system from startup Onward Medical passed another developmental milestone on Wednesday, as the company announced the first successful installation of its brainwave-driven implantable electrode array to restore function and feeling to a patient’s hands and arms. The news comes just five months after the researchers implanted a similar system in a different patient to help them regain a more natural walking gait.

The ARC system used differs depending on how what issue it's being applied to. The ARC-EX is an external, non-invasive stimulator array that sits on the patient’s lower back and helps regulate their bladder control and blood pressure, as well as improving limb function and control. Onward’s lower limb study from May employed the EX along with a BCI controller from CEA-Clinatec to create a “digital bridge” spanning the gap in the patient’s spinal column.

The study published Wednesday instead utilized the ARC-IM, an implantable version of the company’s stimulator array which is installed near the spinal cord and is controlled through wearable components and a smartwatch. Onward had previously used the IM system to enable paralyzed patients to stand and walk short distances without assistance, for which it was awarded an FDA Breakthrough Device Designation in 2020.

Medical professionals led by by neurosurgeon Dr. Jocelyne Bloch, implanted the ARC-IM and the Clinatec BCI into a 46-year-old patient suffering from a C4 spinal injury, in mid-August. The BCI’s hair-thin leads pick up electrical signals in the patient’s brain, convert those analog signals into digital ones that machines can understand, and then transmits them to a nearby computing device where a machine learning AI interprets the patient’s electrical signals and issues commands to the implanted stimulator array. The patient thinks about what they want to do and these two devices work to translate that intent into computer-controlled movement.

How well that translation occurs remains to be seen while the patient learns and adapts to the new system. “The implant procedures involving the Onward ARC-IM and Clinatec BCI went smoothly,” Dr. Bloch said in an press release. “We are now working with the patient to use this cutting-edge innovation to recover movement of his arms, hands, and fingers. We look forward to sharing more information in due course.”

“If the therapy continues to show promise, it is possible it could reach patients by the end of the decade,” Onward CEO Dave Marver said in a statement to Engadget. “It is important to note that we do not expect people with spinal cord injury to wait that long for Onward to commercialize an impactful therapy - we hope to commercialize our external spinal cord stimulation solution, ARC-EX Therapy, to restore hand and arm function in the second half of 2024.”

Onward Medical among a quickly expanding field of BCI-based startups working to apply the fledgling technology to a variety of medical maladies. Those applications include loss of limb and self-regulatory function due to stroke, traumatic brain or spinal cord injury, physical rehabilitation from those same injuries, as well as a critical means of communication for people living with Locked-In Syndrome.

Apple’s watchOS 10 officially became available on September 18, and it brings a new feature in the Mindfulness app that gives you the option of logging your feelings and moods directly on your watch face. These updates will be available if you have an Apple Watch Series 4 or newer model. Here’s how to navigate that new feature.

Malak Saleh

How to log your mood

When you open the Mindfulness app, tap “State of Mind” and then “Get Started” to begin the logging process. From there, you can either log a “momentary emotion” to input how you feel at that instant, or a “daily mood” to report how you felt overall that day.

Malak Saleh

Using the watch’s Digital Crown, you can scroll through seven abstract images with corresponding emotional valences ranging from "very pleasant" to "very unpleasant." Once you select an emotion, you can opt for more logging and go into greater detail about the feelings you’re experiencing (including what's having the biggest effect on you) by selecting options from a drop-down menu.

Malak Saleh

How to view your mood logs

Over time you can keep tabs on your daily logging activity in the Health app under the “Mental Wellbeing” tab. Using a paired iPhone, click “State of Mind” and then open “Show in Charts.” From this page, you can view the type of entries for daily moods or momentary emotions. You also have the option to view lifestyle factors associated with these entries to learn how your moods may correlate with variables like time spent in the sun, sleep trends, and exercise habits.

Malak Saleh

Additionally, specific assessments for depression and anxiety are now accessible in the Health app. You can also export PDFs of personal health reports if you ever need to share logs with a medical professional. You’ll need to open the Health app and click the “Sharing tab” at the bottom of the screen. From there you can choose to “Share with someone,” such as a contact, or “Share with your doctor.” 

If you want to share with your doctor, you can search for specific hospital systems to connect your health data and keep tabs on clinical records. For example, if you were a client at “Green Primary Care” in Huntsville, Alabama, you could directly connect to the patient portal, get secure access to health records, and also share your personal health data with a care team – this is where building a habit of logging daily moods may be helpful for a provider to get a fuller picture on the state of your mental health.

GE Health says it plans to develop an AI-assisted ultrasound imaging tool that is so easy to use, that even healthcare providers without specialized training will be able to operate it. The device's research and development will be funded by a $44 million grant from the Bill & Melinda Gates Foundation, which has historically invested in the roll-out of new technologies in resource-poor settings to address gaps in healthcare access.

GE says the AI-powered imaging technology has been designed to be dispersed to low-and-middle income countries where the services of healthcare providers may be stretched thin. The ultrasound tool will be more effective at providing clear readings of lung and ultrasound scans across maternal and fetal care as well as pediatric lung health. These areas of medicine are particularly notable because maternal and child mortality is mostly preventable if medical intervention occurs early. Proper medical imaging is key to achieving timely diagnosis, guides treatment decisions and can improve treatment outcomes.

GE’s $3 billion ultrasound business, has recently focused on the development pipeline of AI software with the acquisition of med tech companies like Caption Health, which will help design this particular ultrasound device. The company appears committed to a strategy of increasing spending on AI-related projects both now and in the near future.